organization · Reporting owner
OPKO HEALTH, INC.
Disclosed activity across 3 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| VBI Vaccines Inc/BCVBIV · Entity 111039 | 10% owner | January 01, 2017 | November 09, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
VBI Vaccines Inc/BC
Report date January 01, 2017 · Filed November 09, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 6,023,014 |
Reported balance
Holding disclosure · report date 2017-01-01 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 6,023,014 F1: In June 2012, OPKO acquired a 50% stock ownership in SciVac Ltd., a privately held Israeli corporation ("Old SciVac"). In July 2015, Old SciVac completed a reverse takeover (the "Transaction") of Levon Resources Ltd., a Canadian corporation and Levon changed its name to "SciVac Therapeutics Inc." ("SciVac"). At the time the Transaction became effective, OPKO's Old SciVac Shares were exchanged for 185,129,317 common shares of SciVac, and OPKO became the beneficial owner of approximately 24.5% of SciVac. SciVac acquired VBI Vaccines (Delaware) Inc., a Delaware corporation in May 2016, and changed its name to "VBI Vaccines Inc." Subsequently in 2016, OPKO participated in a private placement of VBI shares and also received additional shares of VBI in connection with an anti-dilution clause with respect to the merger in 2016. OPKO's percentage ownership was then approximately 15.1%. At the time of these transactions, the issuer was a foreign private issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: In June 2012, OPKO acquired a 50% stock ownership in SciVac Ltd., a privately held Israeli corporation ("Old SciVac"). In July 2015, Old SciVac completed a reverse takeover (the "Transaction") of Levon Resources Ltd., a Canadian corporation and Levon changed its name to "SciVac Therapeutics Inc." ("SciVac"). At the time the Transaction became effective, OPKO's Old SciVac Shares were exchanged for 185,129,317 common shares of SciVac, and OPKO became the beneficial owner of approximately 24.5% of SciVac. SciVac acquired VBI Vaccines (Delaware) Inc., a Delaware corporation in May 2016, and changed its name to "VBI Vaccines Inc." Subsequently in 2016, OPKO participated in a private placement of VBI shares and also received additional shares of VBI in connection with an anti-dilution clause with respect to the merger in 2016. OPKO's percentage ownership was then approximately 15.1%. At the time of these transactions, the issuer was a foreign private issuer.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Eloxx Pharmaceuticals, Inc.
Report date December 19, 2017 · Filed December 21, 2017
Section 16 reporting ended · disclosed 2017-12-21. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,289,818 |
Reported balance
After 2017-12-19 transaction · row 1
1 source rowRow 1 · 2017-12-19 · Grant · Acquired 495,126 · Balance 1,289,818 F1: On December 19, 2017, the Issuer, Sevion Sub Ltd. ("Acquisition Sub"), and Eloxx Pharmaceuticals Ltd. ("Eloxx"), completed the merger contemplated under that certain Merger Agreement dated May 31, 2017, and pursuant to which Acquisition Sub merged with and into Eloxx, with Eloxx becoming the surviving corporation and a wholly-owned subsidiary of the Issuer. At the effective time of the merger, shares held by existing Eloxx shareholders prior to the Merger was converted, on a pro rata basis, into the right to receive 20,316,656 shares of Issuer common stock, after giving effect to a 1-for-20 reverse stock split that was effected on December 19, 2017. |
Filing footnotes · ownership attribution and instrument terms
F1: On December 19, 2017, the Issuer, Sevion Sub Ltd. ("Acquisition Sub"), and Eloxx Pharmaceuticals Ltd. ("Eloxx"), completed the merger contemplated under that certain Merger Agreement dated May 31, 2017, and pursuant to which Acquisition Sub merged with and into Eloxx, with Eloxx becoming the surviving corporation and a wholly-owned subsidiary of the Issuer. At the effective time of the merger, shares held by existing Eloxx shareholders prior to the Merger was converted, on a pro rata basis, into the right to receive 20,316,656 shares of Issuer common stock, after giving effect to a 1-for-20 reverse stock split that was effected on December 19, 2017.
GeneDx Holdings Corp.
Report date August 15, 2024 · Filed August 19, 2024
Section 16 reporting ended · disclosed 2024-08-19. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 2,646,972 |
Ending reported balance
After 2024-08-19 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2024-08-15 · Sale · Disposed 39,824 · Balance 2,746,972 F1: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.00 to $34.26, inclusive. The reporting person undertakes to provide to GeneDx Holding Corp. (the "Company"), any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in footnote (1) to this Form 4. Row 2 · 2024-08-16 · Sale · Disposed 50,000 · Balance 2,696,972 F2: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.84 to $34.86, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in footnote (2) to this Form 4. Row 3 · 2024-08-19 · Sale · Disposed 50,000 · Balance 2,646,972 F3: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.00 to $35.53, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in footnote (3) to this Form 4. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.00 to $34.26, inclusive. The reporting person undertakes to provide to GeneDx Holding Corp. (the "Company"), any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in footnote (1) to this Form 4.
F2: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.84 to $34.86, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in footnote (2) to this Form 4.
F3: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.00 to $35.53, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in footnote (3) to this Form 4.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 19, 2024 Filed Aug 19, 2024 21:23 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | SaleClass A Common Stock | 50,000 | $34.49 | $1,724,520.00 |
DisclosureSEC source: 0000950170-24-098688 · ownership.xml · nonDerivative · entry 3 OPKO HEALTH, INC. · CIK 0000944809 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,646,972 F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.00 to $35.53, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in footnote (3) to this Form 4. Read SEC document |
| August 16, 2024 Filed Aug 19, 2024 21:23 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | SaleClass A Common Stock | 50,000 | $34.30 | $1,714,850.00 |
DisclosureSEC source: 0000950170-24-098688 · ownership.xml · nonDerivative · entry 2 OPKO HEALTH, INC. · CIK 0000944809 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,696,972 F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.84 to $34.86, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in footnote (2) to this Form 4. Read SEC document |
| August 15, 2024 Filed Aug 19, 2024 21:23 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | SaleClass A Common Stock | 39,824 | $33.08 | $1,317,505.36 |
DisclosureSEC source: 0000950170-24-098688 · ownership.xml · nonDerivative · entry 1 OPKO HEALTH, INC. · CIK 0000944809 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,746,972 F1 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.00 to $34.26, inclusive. The reporting person undertakes to provide to GeneDx Holding Corp. (the "Company"), any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in footnote (1) to this Form 4. Read SEC document |
| August 13, 2024 Filed Aug 14, 2024 20:50 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | SaleClass A Common Stock | 24,987 | $34.76 | $868,503.14 |
DisclosureSEC source: 0000950170-24-097135 · ownership.xml · nonDerivative · entry 2 OPKO HEALTH, INC. · CIK 0000944809 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,786,796 F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.50 to $35.9175, inclusive. The reporting person undertakes to provide to Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in footnote (2) to this Form 4. Read SEC document |
| August 12, 2024 Filed Aug 14, 2024 20:50 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | SaleClass A Common Stock | 59,787 | $33.95 | $2,029,810.50 |
DisclosureSEC source: 0000950170-24-097135 · ownership.xml · nonDerivative · entry 1 OPKO HEALTH, INC. · CIK 0000944809 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,811,783 F1 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.16 to $34.90, inclusive. The reporting person undertakes to provide to GeneDx Holding Corp. (the "Company"), any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in footnote (1) to this Form 4. Read SEC document |
| August 08, 2024 Filed Aug 8, 2024 21:39 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | SaleClass A Common Stock | 100,000 | $31.82 | $3,182,380.00 |
DisclosureSEC source: 0000950170-24-094224 · ownership.xml · nonDerivative · entry 2 OPKO HEALTH, INC. · CIK 0000944809 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,871,570 F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.20 to $32.50, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in footnote (2) to this Form 4. Read SEC document |
| August 06, 2024 Filed Aug 8, 2024 21:39 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | SaleClass A Common Stock | 12,994 | $29.35 | $381,427.18 |
DisclosureSEC source: 0000950170-24-094224 · ownership.xml · nonDerivative · entry 1 OPKO HEALTH, INC. · CIK 0000944809 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,971,570 F1 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.75, inclusive. The reporting person undertakes to provide to GeneDx Holding Corp. (the "Company"), any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in footnote (1) to this Form 4. Read SEC document |
| July 31, 2024 Filed Aug 2, 2024 20:21 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | SaleClass A Common Stock | 88,839 | $33.50 | $2,976,346.37 |
DisclosureSEC source: 0000950170-24-089997 · ownership.xml · nonDerivative · entry 1 OPKO HEALTH, INC. · CIK 0000944809 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,984,564 F1 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.00 to $34.21, inclusive. The reporting person undertakes to provide to GeneDx Holding Corp. (the "Company"), any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in footnote (1) to this Form 4. Read SEC document |
| July 29, 2024 Filed Jul 31, 2024 21:03 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | SaleClass A Common Stock | 50,000 | $33.86 | $1,692,890.00 |
DisclosureSEC source: 0000950170-24-088679 · ownership.xml · nonDerivative · entry 1 OPKO HEALTH, INC. · CIK 0000944809 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,073,403 F1 · balance_after: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from 33.56 to $34.16, inclusive. The reporting person undertakes to provide to GeneDx Holding Corp. (the "Company"), any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in footnote (1) to this Form 4. Read SEC document |
| July 26, 2024 Filed Jul 26, 2024 23:49 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | SaleClass A Common Stock | 60,000 | $33.85 | $2,031,258.00 |
DisclosureSEC source: 0000950170-24-087048 · ownership.xml · nonDerivative · entry 2 OPKO HEALTH, INC. · CIK 0000944809 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,123,403 F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.50 to $34.66, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in footnote (2) to this Form 4. Read SEC document |
| July 24, 2024 Filed Jul 26, 2024 23:49 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | SaleClass A Common Stock | 75,000 | $33.72 | $2,529,105.00 |
DisclosureSEC source: 0000950170-24-087048 · ownership.xml · nonDerivative · entry 1 OPKO HEALTH, INC. · CIK 0000944809 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,183,403 F1 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.33 to $34.33, inclusive. The reporting person undertakes to provide to GeneDx Holding Corp. (the "Company"), any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in footnote (1) to this Form 4. Read SEC document |
| July 23, 2024 Filed Jul 23, 2024 21:16 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | SaleClass A Common Stock | 75,000 | $33.46 | $2,509,245.00 |
DisclosureSEC source: 0000950170-24-085751 · ownership.xml · nonDerivative · entry 3 OPKO HEALTH, INC. · CIK 0000944809 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,258,403 F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.72 to $34.50, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in footnote (2) to this Form 4. Read SEC document |
| July 22, 2024 Filed Jul 23, 2024 21:16 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | SaleClass A Common Stock | 50,000 | $32.61 | $1,630,440.00 |
DisclosureSEC source: 0000950170-24-085751 · ownership.xml · nonDerivative · entry 2 OPKO HEALTH, INC. · CIK 0000944809 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,333,403 F1 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.00 to $33.02, inclusive. The reporting person undertakes to provide to GeneDx Holding Corp. (the "Company"), any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in footnote (1) to this Form 4. Read SEC document |
| July 19, 2024 Filed Jul 23, 2024 21:16 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | SaleClass A Common Stock | 25,000 | $32.29 | $807,250.00 |
DisclosureSEC source: 0000950170-24-085751 · ownership.xml · nonDerivative · entry 1 OPKO HEALTH, INC. · CIK 0000944809 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,383,403 Read SEC document |
| July 17, 2024 Filed Jul 19, 2024 22:46 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | SaleClass A Common Stock | 25,000 | $32.93 | $823,187.50 |
DisclosureSEC source: 0000950170-24-085008 · ownership.xml · nonDerivative · entry 1 OPKO HEALTH, INC. · CIK 0000944809 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,408,403 F1 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.87 to $33.18, inclusive. The reporting person undertakes to provide to GeneDx Holding Corp. (the "Company"), any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in footnote (1) to this Form 4. Read SEC document |
| July 05, 2024 Filed Jul 9, 2024 20:07 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | SaleClass A Common Stock | 36,118 | $28.24 | $1,020,015.66 |
DisclosureSEC source: 0000950170-24-082411 · ownership.xml · nonDerivative · entry 1 OPKO HEALTH, INC. · CIK 0000944809 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,433,403 F1 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.00 to $28.75, inclusive. The reporting person undertakes to provide to GeneDx Holdings Corp. (the "Company"), any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in footnote (1) to this Form 4. Read SEC document |
| July 03, 2024 Filed Jul 3, 2024 20:56 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | SaleClass A Common Stock | 14,082 | $28.23 | $397,491.21 |
DisclosureSEC source: 0000950170-24-081596 · ownership.xml · nonDerivative · entry 3 OPKO HEALTH, INC. · CIK 0000944809 · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,469,521 F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.00 to $28.965, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in footnote (3) to this Form 4. Read SEC document |
| July 02, 2024 Filed Jul 3, 2024 20:56 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | SaleClass A Common Stock | 25,000 | $29.12 | $728,095.00 |
DisclosureSEC source: 0000950170-24-081596 · ownership.xml · nonDerivative · entry 2 OPKO HEALTH, INC. · CIK 0000944809 · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,483,603 F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.31 to $31.20, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in footnote (2) to this Form 4. Read SEC document |
| July 01, 2024 Filed Jul 3, 2024 20:56 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | SaleClass A Common Stock | 50,000 | $26.63 | $1,331,700.00 |
DisclosureSEC source: 0000950170-24-081596 · ownership.xml · nonDerivative · entry 1 OPKO HEALTH, INC. · CIK 0000944809 · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,508,603 F1 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.4607 to $26.95, inclusive. The reporting person undertakes to provide to GeneDx Holding Corp. (the "Company"), any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in footnote (1) to this Form 4. Read SEC document |
| April 11, 2023 Filed Apr 13, 2023 20:46 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | GrantClass A Common Stock | 23,148,148 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-024222 · doc4.xml · nonDerivative · entry 1 OPKO HEALTH, INC. · CIK 0000944809 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 117,433,862 F1 · kind: The Reporting Person is receiving these shares as payment for having achieved a milestone event as described in the Agreement and Plan of Merger and Reorganization, dated January 14, 2022, to which the Reporting Person and the Issuer are parties. Read SEC document |
| January 26, 2023 Filed Feb 1, 2023 01:01 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | PurchaseClass A Common Stock | 14,285,714 | $0.35 | $4,999,999.90 |
DisclosureSEC source: 0001209191-23-005821 · doc4.xml · nonDerivative · entry 1 OPKO HEALTH, INC. · CIK 0000944809 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,285,714 Read SEC document |
| December 19, 2017 Filed Dec 21, 2017 23:27 UTC | Eloxx Pharmaceuticals, Inc. SVOND · Entity 7180 | GrantCommon Stock | 495,126 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-17-066864 · doc4.xml · nonDerivative · entry 1 Opko Health, Inc. · CIK 0000944809 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,289,818 F1 · shares: On December 19, 2017, the Issuer, Sevion Sub Ltd. ("Acquisition Sub"), and Eloxx Pharmaceuticals Ltd. ("Eloxx"), completed the merger contemplated under that certain Merger Agreement dated May 31, 2017, and pursuant to which Acquisition Sub merged with and into Eloxx, with Eloxx becoming the surviving corporation and a wholly-owned subsidiary of the Issuer. At the effective time of the merger, shares held by existing Eloxx shareholders prior to the Merger was converted, on a pro rata basis, into the right to receive 20,316,656 shares of Issuer common stock, after giving effect to a 1-for-20 reverse stock split that was effected on December 19, 2017. F1 · price: On December 19, 2017, the Issuer, Sevion Sub Ltd. ("Acquisition Sub"), and Eloxx Pharmaceuticals Ltd. ("Eloxx"), completed the merger contemplated under that certain Merger Agreement dated May 31, 2017, and pursuant to which Acquisition Sub merged with and into Eloxx, with Eloxx becoming the surviving corporation and a wholly-owned subsidiary of the Issuer. At the effective time of the merger, shares held by existing Eloxx shareholders prior to the Merger was converted, on a pro rata basis, into the right to receive 20,316,656 shares of Issuer common stock, after giving effect to a 1-for-20 reverse stock split that was effected on December 19, 2017. Read SEC document |
| October 30, 2017 Filed Nov 1, 2017 16:11 UTC | VBI Vaccines Inc/BC VBIV · Entity 111039 | PurchaseCommon Stock | 655,738 | $3.05 | $2,000,000.90 |
DisclosureSEC source: 0001209191-17-058591 · doc4.xml · nonDerivative · entry 1 Opko Health, Inc. · CIK 0000944809 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,678,752 Read SEC document |
| September 19, 2017 Filed Nov 7, 2017 21:00 UTC | Eloxx Pharmaceuticals, Inc. SVON · Entity 7180 | Conversion0% Series C Convertible Perferred · Derivative | 66,667 | $0.00 Strike: $0.40 | $0.00 |
DisclosureSEC source: 0001209191-17-059592 · doc4.xml · derivative · entry 2 Opko Health, Inc. · CIK 0000944809 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,250,006 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: The derivative security was previously subject to a "blocker" pursuant to which the reporting person was unable to convert the derivative security to the extent such conversion would result in the reporting person owning more than 4.99%. F3 · derivative.exercise_date: The convertible preferred stock was convertible at any time at the holder's option and had no expiration date. F3 · derivative.expiration_date: The convertible preferred stock was convertible at any time at the holder's option and had no expiration date. Read SEC document |
| September 19, 2017 Filed Nov 7, 2017 21:00 UTC | Eloxx Pharmaceuticals, Inc. SVON · Entity 7180 | ConversionCommon Stock | 1,250,006 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-059592 · doc4.xml · nonDerivative · entry 1 Opko Health, Inc. · CIK 0000944809 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,893,844 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The Reporting Person converted 66,667 shares of 0% Series C Convertible Preferred Stock on September 19, 2017 at a conversion price of $.40 per share, resulting in the acquisition of 1,250,006 shares of Common Stock. The conversion was effected in connection with that certain proposed merger between the Issuer, Sevion Sub Ltd. ("Acquisition Sub"), and Eloxx Pharmaceuticals Ltd. ("Eloxx"), pursuant to which, subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement dated May 31, 2017, Acquisition Sub will merge with and into Eloxx, with Eloxx becoming the surviving corporation and a wholly-owned subsidiary of the Issuer. Read SEC document |
| August 10, 2017 Filed Aug 14, 2017 21:15 UTC | Eloxx Pharmaceuticals, Inc. SVON · Entity 7180 | ConversionConvertible Promissory Note · Derivative | Not disclosed | $0.00 Strike: $0.10 | $250,000.00 |
DisclosureSEC source: 0001209191-17-048791 · doc4.xml · derivative · entry 4 Opko Health, Inc. · CIK 0000944809 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,500,000 shares Expires 2017-08-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: The derivative security was previously subject to a "blocker" pursuant to which the reporting person was unable to convert the derivative security to the extent such conversion would result in the reporting person owning more than 4.99%. F2 · kind: Pursuant to the terms of the Convertible Note, the Reporting Person acquired (i) 2,500,000 shares of Common Stock upon conversion of $250,000 in principal amount of the Convertible Note, and (ii) 63,699 shares of Common Stock in accrued and previously unpaid interest thereon (6,369.86). Read SEC document |
| August 10, 2017 Filed Aug 14, 2017 21:15 UTC | Eloxx Pharmaceuticals, Inc. SVON · Entity 7180 | ConversionConvertible Promissory Note · Derivative | Not disclosed | $0.00 Strike: $0.10 | $150,000.00 |
DisclosureSEC source: 0001209191-17-048791 · doc4.xml · derivative · entry 3 Opko Health, Inc. · CIK 0000944809 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,500,000 shares Expires 2017-11-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: The derivative security was previously subject to a "blocker" pursuant to which the reporting person was unable to convert the derivative security to the extent such conversion would result in the reporting person owning more than 4.99%. F1 · kind: Pursuant to the terms of the Convertible Note, the Reporting Person acquired (i) 1,500,000 shares of Common Stock upon conversion of $150,000 in principal amount of the Convertible Note, and (ii) 63,123 shares of Common Stock in accrued and previously unpaid interest thereon ($6,312.33). Read SEC document |
| August 10, 2017 Filed Aug 14, 2017 21:15 UTC | Eloxx Pharmaceuticals, Inc. SVON · Entity 7180 | ConversionCommon Stock | 2,563,699 | $0.10 | $256,369.90 |
DisclosureSEC source: 0001209191-17-048791 · doc4.xml · nonDerivative · entry 2 Opko Health, Inc. · CIK 0000944809 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,643,838 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: Pursuant to the terms of the Convertible Note, the Reporting Person acquired (i) 2,500,000 shares of Common Stock upon conversion of $250,000 in principal amount of the Convertible Note, and (ii) 63,699 shares of Common Stock in accrued and previously unpaid interest thereon (6,369.86). Read SEC document |
| August 10, 2017 Filed Aug 14, 2017 21:15 UTC | Eloxx Pharmaceuticals, Inc. SVON · Entity 7180 | ConversionCommon Stock | 1,563,123 | $0.10 | $156,312.30 |
DisclosureSEC source: 0001209191-17-048791 · doc4.xml · nonDerivative · entry 1 Opko Health, Inc. · CIK 0000944809 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,080,139 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Pursuant to the terms of the Convertible Note, the Reporting Person acquired (i) 1,500,000 shares of Common Stock upon conversion of $150,000 in principal amount of the Convertible Note, and (ii) 63,123 shares of Common Stock in accrued and previously unpaid interest thereon ($6,312.33). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.